KalVista Pharmaceuticals CCO Nicole Sweeny's Stock Transactions

This Form 4 filing reports stock transactions by Nicole Sweeny, Chief Commercial Officer of KalVista Pharmaceuticals. On May 22, 2026, Sweeny received 5,000 shares of common stock through the vesting and settlement of restricted stock units (RSUs) at $0 per share, bringing her total common stock holdings to 60,780 shares. Concurrently, 5,000 RSUs were settled, leaving her with 40,000 remaining RSUs. On May 26, 2026, she sold 1,489 shares at $26.7778 per share to cover tax withholding obligations related to the RSU vesting, reducing her common stock holdings to 59,291 shares. The RSUs vest quarterly starting August 22, 2024, contingent on continued service. The sale was specifically for tax withholding purposes and not a discretionary transaction.